Mei Ri Jing Ji Xin Wen·2025-06-22 23:20Group 1: Regulatory Support and Industry Development - The National Medical Products Administration (NMPA) has approved measures to optimize the lifecycle regulation to support the innovation of high-end medical devices, focusing on products like medical robots and advanced imaging equipment [1] - The support for high-end medical devices is expected to drive industry upgrades and accelerate the formation of new productive forces in the medical device sector [1] Group 2: Product Approvals and Market Expansion - Aosaikang's subsidiary has received a drug registration certificate for Methotrexate injection, which can treat various cancers, enhancing the company's competitiveness in the oncology market [2] - Anglikang's subsidiary has passed the GMP compliance inspection for its Finasteride raw material production line, paving the way for product commercialization and strengthening its position in the raw material market [3] - Jiuzhoutong's subsidiary has obtained a drug registration certificate for Dexamethasone Sodium Phosphate injection, with sales in public medical institutions reaching nearly 1.2 billion yuan in 2023, a year-on-year increase of 59.27% [4] - Jiuzhoutong aims to achieve a sales revenue of 3.007 billion yuan in 2024, reflecting a year-on-year growth of 21.49% as part of its strategy to expand its product offerings and improve quality [4] Group 3: Leadership Changes - Kangyuan Pharmaceutical's chairman, Xiao Wei, has resigned from his position due to personal reasons but will continue to serve in other key roles, ensuring strategic continuity and stability in corporate governance [5]